moderate disease – Page 13 – Communicable Diseases Research

Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks

Short Communication

Published on 2020-06-032022-10-31
Journal: European journal of pediatrics [Category] COVID-19, MERS, SARS,

Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China

Research

Published on 2020-06-032022-10-29
Journal: JAMA Network Open [Category] COVID-19,

[키워드] acute respiratory syndrome age alanine aminotransferase ALT analyzed Aspartate aminotransferase association AST B cell B cells biochemical Case series case sery caused CD4 Characteristics children CK-MB clinical Clinical characteristics Clinical management collected coronavirus coronavirus disease COVID-19 Critically ill decrease disease severity dysregulation exposure feature finding immune immune response Immunoglobulin Importance Infection Inflammatory cytokine Inflammatory response information interferon γ interquartile range involved laboratory abnormality laboratory-confirmed lactate dehydrogenase LDH liver lymphocyte Lymphocytes lymphopenia measure median Mild mild case mild cases moderate Moderate COVID-19 moderate disease myocardial injury Necrosis neutrophil Neutrophils objective occurred participant Pathogenesis pathogenesis of SARS-CoV-2 pathologic process Patient Pediatric patient Pediatric patients Pneumonia Point positive Relevance reported Result SARS-CoV-2 SARS-COV-2 infection setting severe cases single-center statistically significant difference systemic inflammation T cell T cells with COVID-19 with mild disease Wuhan Wuhan, China
[DOI] 10.1001/jamanetworkopen.2020.10895 PMC 바로가기 [Article Type] Research

COVID-19 in children: a case series from Nigeria

Research

Published on 2020-05-282022-10-28
Journal: The Pan African Medical Journal [Category] COVID-19, MERS,

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

주로 경증에서 중등도의 코로나바이러스 질환 환자의 하이드록시클로로퀸 2019: 공개 라벨, 무작위 대조 시험

Research

Published on 2020-05-142022-08-09
Journal: The BMJ [Category] Fulltext, MERS, 임상,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse adverse event adverse events analysed Analysis assigned China Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 covid-19 treatment centre diarrhoea dose Efficacy and safety event followed by Government group hospital Hydroxychloroquine hydroxychloroquine group hydroxychloroquine non-recipient hydroxychloroquine non-recipients hydroxychloroquine recipient hydroxychloroquine recipients Intention intention to treat laboratory confirmed covid-19 Loading dose maintenance dose Mild mild to moderate mild to moderate disease moderate moderate disease negative Negative conversion non-recipients objective open open label outcome measure participant Patient patients principle Probability randomisation randomised controlled trial recipients reported respiratory Result safety population Serious Adverse Events setting severe acute respiratory syndrome Coronavirus severe disease significantly higher Standard of care symptom onset Treatment Trial registration virus were recorded
[DOI] 10.1136/bmj.m1849 PMC 바로가기 [Article Type] Research

Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China

Medicine

Published on 2020-05-122022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] Admission age analyzed asymptomatic patient asymptomatic patients average biochemical blood cell count caused Characteristics Chest computed tomography Chest CT scans China Chronic diseases clinical clinical characteristic Clinical course clinical outcomes clinical symptom complex complications coronavirus disease cough COVID-19 COVID-19 case COVID-19 patient COVID-19 patients Critically ill diarrhea difference disease disease severity Duration Epidemiologic characteristic fatigue feature Fever FIVE granulocyte granulocyte count groups Hospitalization Hospitalized identify infiltration Liaocheng lymphocyte Lymphocyte count majority Mild moderate moderate disease Mortality Older Onset outcome Patient patients patients with COVID-19 Pneumonia quarantine reason recorded Release released retrospective Seven severe disease Shortness of breath similarity sore throat Symptom symptom onset the patient vomiting white White blood cell
[DOI] 10.3389/fmed.2020.00210 PMC 바로가기 [Article Type] Medicine

Novel coronavirus disease (COVID-19) in children

Article

Published on 2020-04-212022-10-29
Journal: Turkish Journal of Medical Sciences [Category] COVID-19, SARS,

Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset

Research Article

Published on 2014-08-212022-10-29
Journal: PLoS Pathogens [Category] Coronavirus, MERS,

[키워드] addition Analysis animal model cause common Comorbidities comparable complicate demonstrated different time point Dipeptidyl peptidase 4 disease Disease model Efficacy evaluate expression Extensive humans immune inflammatory pathways Interaction intranasal lack lesion lethal lung marmoset marmoset model MERS-CoV MERS-CoV infection Middle East Mild modeling moderate disease MOST ocular Pathogenesis post inoculation potential therapeutic agent predicted Protein receptor required respiratory syndrome coronavirus rhesus RNAseq robust severe disease severe pneumonia severity spike glycoprotein the disease translated treated treatment strategy Vaccine Viral load virus entry was tested while
[DOI] 10.1371/journal.ppat.1004250 PMC 바로가기 [Article Type] Research Article